In last trading session, Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) saw 0.4 million shares changing hands with its beta currently measuring -0.90. Company’s recent per share price level of $326.79 trading at $6.86 or 2.14% at ring of the bell on the day assigns it a market valuation of $7.22B. That closing price of MDGL’s stock is at a discount of -15.51% from its 52-week high price of $377.46 and is indicating a premium of 42.16% from its 52-week low price of $189.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.35 million shares which gives us an average trading volume of 369.66K if we extend that period to 3-months.

For Madrigal Pharmaceuticals Inc (MDGL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 11 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -3.83 in the current quarter.

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) trade information

Upright in the green during last session for gaining 2.14%, in the last five days MDGL remained trading in the green while hitting it’s week-highest on Friday, 04/25/25 when the stock touched $326.79 price level, adding 0.85% to its value on the day. Madrigal Pharmaceuticals Inc’s shares saw a change of 5.90% in year-to-date performance and have moved 8.33% in past 5-day. Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) showed a performance of -2.11% in past 30-days. Number of shares sold short was 4.0 million shares which calculate 11.29 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 355.5 to the stock, which implies a rise of 8.08% to its current value. Analysts have been projecting 111 as a low price target for the stock while placing it at a high target of 410. It follows that stock’s current price would jump 66.03% in reaching the projected high whereas dropping to the targeted low would mean a gain of 66.03% for stock’s current value.

Madrigal Pharmaceuticals Inc (MDGL) estimates and forecasts

This year revenue growth is estimated to rise 227.34% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 113.15M for the same. And 13 analysts are in estimates of company making revenue of 138.68M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -32.06% during past 5 years.

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)’s Major holders

Insiders are in possession of 8.79% of company’s total shares while institution are holding 105.14 percent of that, with stock having share float percentage of 115.27%. Investors also watch the number of corporate investors in a company very closely, which is 105.14% institutions for Madrigal Pharmaceuticals Inc that are currently holding shares of the company. JANUS HENDERSON GROUP PLC is the top institutional holder at MDGL for having 2.49 million shares of worth $696.33 million. And as of 2024-06-30, it was holding 11.6142 of the company’s outstanding shares.

The second largest institutional holder is AVORO CAPITAL ADVISORS LLC, which was holding about 2.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6042 of outstanding shares, having a total worth of $575.88 million.

On the other hand, JANUS INVESTMENT FUND-Janus Henderson Forty Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 632.3 shares of worth $206.63 million or 2.86% of the total outstanding shares. The later fund manager was in possession of 515.67 shares on Dec 31, 2024 , making its stake of worth around $168.51 million in the company or a holder of 2.34% of company’s stock.